COPD (chronic obstructive pulmonary disease) causes chronic oxygen deprivation, and HBOT sharply increases available oxygen, so they seem like a natural pairing. The reality is more complicated. COPD is a relative contraindication to hyperbaric oxygen therapy, not an indication for it. As of 2026, no pulmonology guideline (including GOLD) recommends HBOT for COPD, and for patients with severe emphysema or bullae it carries real risk. The distinction between supplemental oxygen (which many COPD patients use) and HBOT (a very different intervention) is where any honest answer starts. COPD is one of several chronic conditions people ask about for hyperbaric therapy.
Relative contraindication: a condition that raises the risk of a treatment enough to require careful evaluation and specialist oversight, but does not absolutely rule it out. Bullae: large air-filled sacs formed when emphysema destroys alveolar walls; they trap air and can rupture under pressure. Hypercapnia (hypercarbia): elevated carbon dioxide in the blood, common in advanced COPD.
Is a hyperbaric chamber safe for COPD?
Only with careful screening, and never as a COPD treatment. COPD is a relative contraindication to HBOT. According to StatPearls, the only absolute contraindication to HBOT is an untreated pneumothorax, while “chronic obstructive pulmonary disease is a relative contraindication to HBOT due to the risk of hypercarbia,” and asymptomatic bullae and blebs are relative contraindications “due to the risk of air trapping.”
The mechanism of concern is physical. Emphysematous lungs trap air, and damaged alveoli can form bullae. During pressurization, trapped air cannot equilibrate normally, creating a risk of alveolar rupture and pneumothorax (a collapsed lung). The patients who might intuitively seem to benefit most from more oxygen, those with severe emphysema and chronic hypoxia, are often the least safe candidates for the pressurized environment. Our guide to hyperbaric chamber side effects covers the pulmonary contraindications in full.
There is reassuring tolerability data for properly screened patients. In a 2019 prospective cohort of 88 patients (Hadanny et al., BMC Pulmonary Medicine), 60 HBOT sessions at 2 ATA produced no significant change in FEV1 (p=0.163) or FEV1/FVC (p=0.435), and the authors concluded the protocol is “safe and has no negative impact on pulmonary functions.” A 2023 longitudinal study of 86 patients (Brenna et al., PLoS One) reached the same conclusion, finding no significant change in FEV1, FVC, or FEF25-75 “regardless of pre-existing respiratory disease,” including COPD. Tolerated is not the same as beneficial, though: neither study showed HBOT improving COPD.
What is the difference between home oxygen and HBOT for COPD?
They are different therapies with different risks, and confusing them is the most common mistake COPD patients make. Supplemental oxygen delivers 24 to 40% oxygen at normal atmospheric pressure to correct resting hypoxemia. HBOT delivers 100% oxygen at 2.0 ATA or higher inside a sealed pressurized chamber, raising both the partial pressure of oxygen and the physical pressure on every air-containing cavity, including the lungs.
Supplemental Oxygen vs HBOT for COPD
| Feature | Supplemental Oxygen | Hyperbaric Oxygen (HBOT) |
|---|---|---|
| Oxygen concentration | 24-40% (adjustable) | 100% |
| Pressure | 1 ATA (normal) | 2.0-3.0 ATA |
| Setting | Home or portable | Clinical hard chamber |
| Role in COPD | Mainstay for resting hypoxemia | Not indicated; relative contraindication |
| Barotrauma / air-trapping risk | None | Real, especially with bullae |
| Evidence in COPD | Improves survival in chronic hypoxemia | No guideline support |
Supplemental oxygen does not pressurize the thorax; HBOT does. That single difference is why the two cannot be equated for a patient with air trapping and bullae. For the home-oxygen side of COPD management, see our guide to oxygen therapy for COPD.
Does HBOT help COPD?
No controlled evidence shows HBOT improves COPD, and no major pulmonology guideline endorses it. HBOT cannot reverse the structural damage (destroyed alveoli, airway remodeling) that defines the disease. The two best human studies on HBOT and lung function, cited above, found no change in spirometry, which means HBOT neither harms nor helps pulmonary function in screened patients.
The only supportive signal is preclinical. A 2024 study in the Tropical Journal of Natural Product Research exposed COPD animal models to HBOT and reported a significant increase in superoxide dismutase (antioxidant) activity and a significant decrease in inflammatory cell expression in lung tissue, alongside a non-significant drop in IL-1beta. The authors framed HBOT as a possible adjuvant. These are rat-model findings and do not establish clinical benefit in humans.
What actually helps COPD?
The interventions with real evidence come from the GOLD (Global Initiative for Chronic Obstructive Lung Disease) report, and none of them is HBOT:
- Smoking cessation: the single most effective intervention at any stage, and the only one shown to alter the disease’s natural history.
- Inhaled bronchodilators: long-acting LABAs and LAMAs are foundational for symptom control.
- Inhaled corticosteroids: for appropriate patients, typically those with frequent exacerbations.
- Long-term supplemental oxygen: improves survival in patients with significant resting hypoxemia.
- Pulmonary rehabilitation: the most evidence-based non-drug intervention, improving exercise capacity, quality of life, and hospitalization rates.
- Surgery: lung volume reduction or transplant for selected severe cases.
Pulmonary rehabilitation, not HBOT, is the appropriate next step for a COPD patient seeking treatment beyond medication, and it is covered by Medicare and most commercial insurers for eligible patients. HBOT should not be pursued instead of, or before, these established treatments.
Can COPD patients ever have HBOT?
Yes, for a separate qualifying indication, after pulmonary clearance. A COPD patient with a diabetic foot ulcer or radiation-injury wound may still receive HBOT if pulmonary assessment shows the risk is manageable. That evaluation is mandatory and includes pulmonary function testing, a chest CT to identify bullae and gauge emphysema extent, assessment of CO2 retention (retainers need specific protocols), and pulmonologist clearance. In patients with large bullae or severe emphysema, HBOT may be contraindicated even for an otherwise approved indication.
CO2 retention deserves specific attention. In advanced COPD, respiratory drive can shift toward a CO2-based stimulus. Breathing very high oxygen concentrations can, in theory, blunt that drive and worsen hypercapnia, which is why HBOT for these patients belongs at a hospital-based program with respiratory-medicine backup rather than a standalone wellness clinic. Our articles on HBOT for wound healing and HBOT for diabetes cover the non-respiratory indications where a COPD patient might legitimately be treated. Asthma raises similar air-trapping questions, addressed in our guide to hyperbaric chambers and asthma.
Frequently Asked Questions
I use supplemental oxygen at home for COPD. Does that mean I’m a candidate for HBOT?
No. Home supplemental oxygen and hyperbaric oxygen therapy are different interventions. Needing supplemental oxygen for COPD does not make you a candidate for HBOT; the underlying lung disease may create air-trapping and CO2-retention risks that make HBOT inappropriate. COPD is a relative contraindication (StatPearls, 2025). A pulmonologist and hyperbaric physician need to evaluate your specific lung function before any HBOT consideration, and only for a separate qualifying indication.
Can HBOT improve my lung function in COPD?
No. HBOT cannot reverse the structural damage (emphysema, chronic bronchitis) that causes COPD, and it cannot restore destroyed alveoli or reverse airway remodeling. Two prospective studies (Hadanny 2019, n=88; Brenna 2023, n=86) found no significant change in spirometry after serial HBOT, including in patients with pre-existing lung disease. No pulmonology guideline recommends HBOT to improve lung function in COPD.
Is HBOT safe after a COPD exacerbation?
Immediately after a COPD exacerbation, when the patient may be unstable and the lungs inflamed and air-trapping, HBOT would be particularly risky. At minimum, the patient should be clinically stable, back to baseline function, and fully evaluated by a pulmonologist before any HBOT is considered for a separate qualifying indication. This is a decision for the treating pulmonologist and hyperbaric physician together, not a self-referral.
What about mild HBOT (1.3 ATA soft chambers) for COPD?
The pressure increase in a 1.3 ATA soft chamber is lower than a hard-shell medical chamber, which somewhat reduces barotrauma risk. But there is no clinical evidence that mild HBOT benefits COPD, and the core concerns about air trapping and CO2 management still apply. Existing human evidence at higher pressures (Hadanny 2019, Brenna 2023) shows no lung-function benefit, so mild HBOT should not be used for COPD without physician oversight.
Sources
- Cooper JS, Hanley ME, et al. “Hyperbaric Oxygen Therapy Contraindications.” StatPearls, NCBI Bookshelf NBK557661, updated 2025. NCBI
- Hadanny A, Zubari T, Catalogna M, et al. “Hyperbaric oxygen therapy effects on pulmonary functions: a prospective cohort study.” BMC Pulmonary Medicine, 2019;19:148. PMC
- Brenna CTA, Khan S, Djaiani G, et al. “Pulmonary function following hyperbaric oxygen therapy: A longitudinal observational study.” PLoS One, 2023;18(5):e0286353. PMC
- “Effects of Hyperbaric Oxygen Therapy on Lungs Histopathology of Animal Models with Chronic Obstructive Pulmonary Disease.” Tropical Journal of Natural Product Research, 2024;8(9). TJNPR
- Global Initiative for Chronic Obstructive Lung Disease. “Global Strategy for Prevention, Diagnosis and Management of COPD: 2024 Report.” GOLD
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
